title: Blood disorders after kidney transplantation.
abstract: Post transplant anemia (PTA) is a common issue in kidney transplant recipients. Most importantly it is associated with an impaired allograft function. Other important factors associated with PTA are immunosuppressive drugs (MPA, AZA and SRL), iron deficiency, infections (Parvo B19), older donor age, rejection episodes, an increased inflammatory state, and erythropoietin hyporesponsiveness. As there are no adequately powered RCTs in the kidney transplant population on anemia treatment with ESA, we have to rely on what we know from the large RCTs in the CKD population. The recently published KDIGO guidelines do not recommend treatment with ESA if Hb is >10 g/dl. Repletion of iron stores is emphasized. Post transplant leukopenia (PTL) and thrombocytopenia (PTT) are frequent complications especially in the first six months after kidney transplantation. Myelosuppression caused by immunosuppressive agents (MPA, AZA, SRL, rATG), antimicrobial drugs (VGCV), and CMV infection is the predominant cause. There are no widely accepted guidelines on treatment strategies, but most often dose reduction or discontinuation of causative medication is done. Most clinicians tend to decrease MPA dose, but this is eventually associated with an increase in acute rejection episodes. VGCV dose reduction (preemptive treatment instead of CMV prophylaxis) may be a successful strategy. In severe cases G-CSF treatment is an important management option and seems to be safe.
authors.affiliation: Department of Nephrology, KH Elisabethinen, Linz, Austria.
authors.forename: Roman
authors.initials: R
authors.lastname: Reindl-Schwaighofer
authors.affiliation: Department of Nephrology, KH Elisabethinen, Linz, Austria; Department of Nephrology, Medical University of Vienna, Vienna, Austria. Electronic address: rainer.oberbauer@meduniwien.ac.at.
authors.forename: Rainer
authors.initials: R
authors.lastname: Oberbauer
mesh_terms: D000740:Anemia / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006084:Graft Rejection; D006085:Graft Survival; D006402:Hematologic Diseases / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000379:methods; D007970:Leukopenia / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology; D008297:Male; D015995:Prevalence; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology